We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Track real-time Director Deals activity on the London Stock Exchange (LSE)
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Eden Research Plc | EDEN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.55 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.55 | 3.55 | 3.55 | 3.55 | 3.55 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 15/7/2025 07:37 by supersonico when the EDEN share price was 3.55p. So imo..Eden and Greenlight are doing field trials. Greenlight encapsulated with SustainE trademarked as Benchmark. This is Insecticide 2. Greenlight will be publishing details of their product in the not to distant with EPA already familiar with both companies products which will be regulated as Biopesticides. All this and the delayed RNS's is NDA so Oberon / Corteva etal can come in and shovel up large chunks of cheap shares while Eden thanks their long term long suffering emancipated share holders for support. Time for a cosy Inside Eden.. |
Posted at 09/7/2025 08:33 by investingisatrickygame when the EDEN share price was 3.75p. "I didn’t know they said they didn’t need cash at the AGM. Are we certain ? - it wasn’t in the presentation. I do believe this board but because of AIM experiences I need reassurance."It has been said so many times over recent month including other recorded presentations. Now I accept 'never say never', but I personally choose to believe that circumstances today are materially different from when they last raised cash. For me, it is all around the 3 pending RNS's, so to be a Parrot 1) Esseva France to treat Powdery Mildew 2) Ecovelex for the whole of Europe 3) Insecticide commercial agreement(s) These are material RNS's because we are told and know that 1) estimates to increase annual revenue in France up to 10*, 2) there is nothing else to treat this predicament and the problem is huge and 3) Eden has stated that this will likely be their biggest product to-date and we already have indicative numbers for Ecovelex, so we can go beyond that. That is going to cost someone(s) when those commercial agreements are signed. The above will turn Eden cash positive as the Chairman has stated and will push Eden into profit. Eden forecast 2026, but that may even come in 2025. These revenues will build rapidly in the case 0f 1 and 2 in a short period for reasons the Company has mentioned. The hope is that these events will raise the Eden share price substantially. Thereafter, we know we can look towards a potato blight solution and insecticide 2 whether that is with Greenlight as Supersonico infers or not. Our existing products will deliver wider geographical approvals and some label extensions. Eden should be in good shape after these RNS's and be seen as a totally different company to the good. Who knows what good things will or might transpire then. |
Posted at 08/7/2025 21:10 by supersonico when the EDEN share price was 3.75p. Alchemy,Below is my Eden / GL collaboration thesis; Here is Ken Narva talking about his work on bio capsules; Ken Narva 27 Mar 2023. "so we've come up with a delivery system that's built on naturally occurring bio capsule that has no activity on its own and we found Ways by partnering with people at the University of Massachusetts who work on RNA Therapeutics for different drug delivery purposes um we've come up with a mechanism whereby we can stabilize and load RNA into these biocapsules now this this is a a really important advancement uh gives us the ability to put RNA in stabilize it then tune its release for when it hits the right physiological environment in the insect gut um so that's that's a clear advantage over some of the microbial production systems that you'll read about that might be in other companies platforms the ability to tune these exactly the way we want is is really important and the graph shows actually some data from Sean's team where we did a field trial with these encapsulated rnas on Diamondback moth and on the very left hand side of that graph you'll see the untreated control and what's being measured here is defoliation so the amount of consumption of leaf by the insects so you see about a 40 percent defoliation and that's a typical field rate of damage you see the commercial standard is the next light green bar and you know we're doing pretty well with our two sequence or their sequence rather at two different rates in the dark green bars so it's a relatively High rate of application in this first trial but I think this is one of the first examples of controlling Lepidoptera effectively in the field with RNA in this case delivered by our delivery platform even more exciting I would say and and working up the the delivery system uh we made a discovery that the bio capsule plus certain co-formulants uh can exhibit an increased activity so this is a little bit of a complex slide what it shows is in the light green bars various treatments that don't have any bio capsule and then in their dark green increasing concentrations of Bio capsule along with increasing concentrations of the scope formulate so um co-formulant alone the first three uh light green bars you see there's there's very little activity there and then you add in more code formula and more bio capsule and you get very good production protection against defoliation so this was uh really exciting to us because now it suggests that not only not only do we have a platform of delivery where we can deliver RNA we can begin to add in other components to further enhance our overall activity and best Spectrum in the field another attribute of this system is its ability to reduce the dose response in resistant insects so you heard earlier that one of the the main things along with residue and registration was to be able to overcome insect resistance so this is work that's been done in the lab with this particular strain of uh Diamondback moth it's resistant to insecticides a little bit of complex data here to look at but on the left hand upper panel you'll see the bio capsule alone and there's really no mortality there against the dbm and then on the right hand part of that graph is you increase bio capsule with the co-formulant you know we're achieving up to nearly 100 percent mortality on in insecticide resistant Diamondback moth so that's a really important Discovery for us if you graph that out and just think about it on the right hand panel there's a dose response curve shown in Gray so if you take the skill formula and and do some dose testing and then add in the the bio capsule you shift that dose response curve to a more sensitive rate that can be close to two orders of magnitude and then on the bottom part of the graph if you express that then as a resistance ratio we've lowered the resistance ratio that is increase the sensitivity from a calculated number of 151 in this case to about 12. so over 10 fold reduction in resistance Ratio or increase in susceptibility so now we've got a platform we can deliver RNA we can load it we can tune it and it's got attributes of overcoming resistance this has also been shown here in the the greenhouse kind of another intermediate step in the way but increased bio capsule in dark green along with co-formulant at increasing rate you see the the decrease in defoliation so more examples of plant protection and then some pictures on the inside on the right untreated control top right or top left formulant some damage on the middle and then the bio capsule political formula is essentially clean from from feeding damage it might be a little bit hard to see but that's if you think about the dark spots on the top onto your control that's what you see a reduction of an elimination of uh with the biotech so plus go Parliament so last slide for me I'll take it back to the beginning of the field data you know first demonstration of double stranded RNA controlling lepid Opera in the field underpinning that is rnai from a particular sequence that we've worked on for a while now um it's got really good lethality when one treats Diamondback moth cell lines with it and you under look into that further and you can see the reduction in gene expression indicating rnai is the mode of action so we've come a long way in the last two or so years with our LEP program it's now got uh the ability to be broadened out Beyond Diamondback moth we've shown these same sort of results with fall army worm and so we'll build out Spectrum as we go forward with this this program" @1hr 14mins I assume that his biocapule commentary is related to the patent application dated 31.10.2023 below; PESTICIDAL COMPOUNDS AND THEIR USE are Gary Ostroff related to University of Massachusetts. Ostroff and his team are core to Eden's IP. See post 20461 and 20291 for further detail of Eden funded research. In this video Narva talks about bio capsules which the patent says are comprised of 'yeast particles comprising yeast cell wall components'. This sounds like Sustaine which Ostroff etal patented. Narva goes on to talk about 'co-formulants' this also sounds like SustainE where the co formulants are essential oils. Andrey Zarur tells us in answer to a audience question ..so presumably unscripted..here that they encapsulate the RNA in an essential oil. "if you put a single strand of RNA in nature it's gone within 15 seconds if you have a double strand of RNA it lasts for about 24 hours now 24 hours is not enough so what we do is we encapsulate that RNA in something very simple basically on essential oils natural oils" @41.42m So Narva talks of a bio capsule and a co formulant and Zarur tells us essential oils are involved so we can assume the co formulants are essential oils. We know that SustainE tech involves the 'Incorporation of a terpene or other therapeutic component in a hollow glucan particle or cell wall particle reduces the rate of release and degradation, thus increasing the duration of action of the molecule in the soil or on the plant'. Further ..Zarur tells us that his formula is - Built with EPA-registered ingredients - Aligns with standard agronomic practices - Designed for cost-effective commercialization that works for farmers - Avoiding the use of costly and potentially dangerous encapsulation technologies that have been ruled out by regulatory authorities This safety and regulatory profile matches Eden's . Other circumstantial indicators include Eden's announcement of Insecticide 2 in a puzzling investor presentation that repeated much of an earlier presentation and the reasons given for it where not convincing but it did have undeclared functions imo which were to announce the following; 1) Delayed insecticide 1 announcement... Reset of investor expectations. 2) Fungicide 2 3) Insecticide 2 targeting Lepidoptera We learn that Insecticide 2 coincidentally targets Lepidoptera which is largely the focus of the earlier mentioned Ostroff / Greenlight patent- PESTICIDAL COMPOUNDS AND THEIR USE Smith adds to the intrigue by being very muted about insecticide 2 and does not expand in anyway on the familiar working with partners or trials narrative as he does readily when describing Insecticide 1 or Fungicide 2. Also notable and running in parallel to these developments is funding from political sources ...firstly the notification that the 'EIB backs GreenLight Biosciences with €35M loan to replace traditional chemical pesticides using power of RNA' and second, GreenLight Bio closes Series C with $25M from Just Climate lastly GL 2024-07-30 TM application; Mark For: BENCHPRESS™ trademark registration is intended to cover the categories of biological compositions for agricultural purposes, and not medical or veterinary purposes, namely, for crop protection and to improve plant health and plant yield; biological compositions for agricultural purposes, and not medical or veterinary purposes, namely, for enhancing the activity of pesticides, acaricides, and insecticides and for reducing the effective dose of pesticides, acaricides, and insecticides; bio-fertilizers; bio-stimulants; Listed above are the picture or puzzle pieces that I see and why I consider a monumental GL / Eden partnership announcement is inthecoming. AWGATWT..your welcome. |
Posted at 16/6/2025 10:03 by supersonico Arian Mani.MSc by Research in Plant Biochemistry as part of the Seed science group at Royal Holloway, University of London in collaboration with a Eden Research PLC. Investigating the effects of terpenes on germination and starch mobilisation of cereal crops at different temperatures Sean Smith CEO at Eden Research PLC Nice, Arian. We enjoyed working with you and congrats on your work! Reply 1 Comment on Sean Smith’s comment James Mani Author MSc in Plant Biochemistry & Molecular biology | Sustainability | Environmental Security | Agriculture. 1y Sean Smith Thank you for the opportunity Sean. It has been a great experience working with yourself and Eden Reply James Hourston Lead Research Scientist in Biological Efficacy at Eden Research plc Great picture and some great work Arian. |
Posted at 13/6/2025 09:43 by supersonico Investing.Eden has said it does not need cash but it would help accelerate projects that would be on the back burner or fungicide 2. Any purchase up to 19.99% I understand would not necessitate an offer I think? Eden not needing cash might not be the primary issues for Corteva who may want a different relationship with more influence and a place on the board and since all the Corteva Eden collaborations are Sumitomo related the bigger picture will always have a Sipcam dynamic. Eden have to appear confident as a negotiating position and Corteva know they have Syngenta in play to balance out Corteva's dominant position but Corteva do have the publicly stated established relationship where as Syngenta has not been disclosed. This all does not explain Oberon's role unless they are involved in a deal that includes Corteva plus Oberon clients. |
Posted at 13/6/2025 08:42 by investingisatrickygame Super,if you are correct, Corteva could acquire a position in Eden by going to market. I think it is called a Tender Offer. In doing so they could seek to acquire, say, 20% of the Company and offer ALL shareholders X pence. So they would have a stake in Eden and no doubt a stronger working relationship. Now, that wouldn't be a cash injection into Eden, but Eden has said it doesn't need cash. Therefore, it must know what revenues will come into the Company this year with some certainty or perhaps there is a transactional event elsewhere, logically around the insecticide wouldn't you think? In any event, Eden appears confident and whether or not Corteva wants a piece of Eden, we will have to wait and see. |
Posted at 15/5/2025 21:43 by investingisatrickygame It is worth noting in the 2020 AGM Q and A, Eden answered market size and penetration for its forthcoming insecticide as follows:-"As we have communicated, this is an opportunity where the addressable market in the EU and US alone is over €850 million. It is generally accepted that a market penetration of between 5 and 10 percent of the total addressable market is achievable with products that fully address the needs of growers." SOURCE: hxxps://www.edenrese In the 13/2/2025 IMC presentation ( and that of yesterday too, Eden said the revenue potential for the same insecticide is now €33 million on a global basis whereas previously is was €42.5- €85 million per annum, purely for the US and Europe. This is quite a significant difference in monetary terms, % terms & geography. More so when you roll this over the life of the regulatory approvals that will be given. As such, the target potential globally of €135 million per annum on Eden's first 4 products (Mevalone/Esseva, Cedroz, Ecovelex and the as yet unnamed insecticide) seems to be to be somewhat understated to me. Why has Eden shrunk the value, but expanded the geography? |
Posted at 13/5/2025 07:36 by investingisatrickygame Morning Super,Well, we are told that Corteva in France with Esseva (Mevalone re-branded under their distributor deal) will do 10* previous sales when it is approved for Powdery Mildew. California has an addressable market of €94 million, Sipcam are a perfect partner and are chomping on the bit to get going in the US. Effectively, California is the market. It is clear that California alone on just Mevalone could and likely will double Eden's current turnover of £4.4 Million. Eden needs 5% of that market. Did Eden launch in the US to get less that a 5% market share? I doubt it very much. MNS, that label extension is extremely helpful and valuable for Eden. Much as you may mock, perhaps through understandable investment disappointment in Eden thus far, this is in my opinion, a material label extension that shareholders should be excited about. I'm pretty sure both Eden and Sipcam are and I choose to believe they haven't increased revenue targets this year based on this approval as they are being extremely cautious, likely unnecessarily so given it is available for the 2025 season. We now await the three key RNS's, all due and I personally expect those three RNS's to appropriate fair value in the share price which should be north of 20p and some. Time will tell. |
Posted at 26/4/2025 10:19 by investingisatrickygame Morning Super,Let's add to post 20854 shall we In the recent Times newspaper article and the post on Linkedin for the same we had the following comments " As one of the leading independent biopesticide companies developing natural crop protection solutions, Eden is leading the charge to replace conventional chemistry in the face of increasing regulatory and consumer pressure. QUESTION: In what way is Eden 'one of the leading'? Can that be explained and quantified? If so, it would be helpful to better understand this QUESION: Can Eden please explain how it is 'leading the charge' and what does this look like? From the article 'We should really clean up there' in regards to Europe and Mevalone @There is huge growth opportunity' Also that Eden will be profitable in 2026 Two years ago the Chairman at the AGM closed by saying 'you will look back in 2 years and realise what a game-changer Ecovelex is' There is so much to explore and explain to propel the share price. I could make a much longer list from Eden's statements |
Posted at 02/4/2025 16:05 by kenmitch supersonico.Two key points in response to your questions. 5 up ticks for your post shows there are still a few as disillusioned as you are about EDEN. And the share price down 99% shows clearly what’s wrong with your hypothesis. Here’s a link for this thread (post 4000) in June 2018, so nearly 6 years ago. What does it show? Just like now; post after post on Eden from supersonico. You’ve spent so many years here wasting your time imo posting over and over again almost every day, while the share price, apart from occasional bounces, has fallen relentlessly. Surely you and the few others posting regularly here can see the simple investment case for EDEN? It’s don’t buy until clear evidence of increased sales. IF that ever happens, which looks unlikely, EDEN could at last see a sustained rising share price, if those increased sales are then followed by more still. Until that day EDEN is dead money at best, and at worst if they can’t get support for yet another fund raise, EDEN is going to go bust. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
